Financial Analysis: Agenus (NASDAQ:AGEN) & Eiger Biopharmaceuticals (EIGR)
Eiger Biopharmaceuticals (NASDAQ: EIGR) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.
This is a breakdown of recent ratings for Eiger Biopharmaceuticals and Agenus, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation & Earnings
This table compares Eiger Biopharmaceuticals and Agenus’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Eiger Biopharmaceuticals||N/A||N/A||-$47.08 million||($5.30)||-1.70|
|Agenus||$22.57 million||16.90||-$126.99 million||($1.17)||-3.20|
Eiger Biopharmaceuticals has higher earnings, but lower revenue than Agenus. Agenus is trading at a lower price-to-earnings ratio than Eiger Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
47.1% of Eiger Biopharmaceuticals shares are held by institutional investors. Comparatively, 37.9% of Agenus shares are held by institutional investors. 28.8% of Eiger Biopharmaceuticals shares are held by insiders. Comparatively, 7.9% of Agenus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Eiger Biopharmaceuticals and Agenus’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Eiger Biopharmaceuticals has a beta of 2.55, meaning that its stock price is 155% more volatile than the S&P 500. Comparatively, Agenus has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500.
Eiger Biopharmaceuticals beats Agenus on 8 of the 12 factors compared between the two stocks.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.
Agenus Company Profile
Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company’s discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company’s vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.